Supriya Lifescience’s stock saw a 2% rise following the inauguration of its new multipurpose Active Pharmaceutical Ingredients (API) production block, Module E, at its Lote Parshuram site in Maharashtra on December 17, 2024.
The ₹125 crore facility boosts production capacity by 335 kiloliters, increasing the site’s total capacity from 597 KLPD to 932 KLPD, a 55% growth.
Supriya Lifescience’s stock opened at ₹723.00, reaching a high of ₹742.65 and a low of ₹716.70 during the trading session. With a 52-week high of ₹835.20 and a low of ₹270.00, the stock has shown significant volatility.
The state-of-the-art facility aligns with Supriya Lifescience’s strategic goal of expanding R&D and enhancing its innovative product pipeline. It plays a critical role in the commercialization of niche therapeutic products, strengthening the company’s position in global pharmaceuticals.
Key Highlights:
- Backward Integration: Offering economies of scale and competitive advantages.
- Infrastructure: 5,000 sq. meters with optimized workflows across four levels.
- Advanced Equipment: 33 reactors, ranging from 1.6 KL to 16 KL.
- Automation: High-standard process control and material handling systems.
- Adaptability: Flexible for diverse unit processes and future scaling.
As of 10:16 am, Kfin Technologies shares were trading 2.23% higher at Rs 734.00 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
